Efficacy and safety of levetiracetam versus phenytoin as second-line drugs for the treatment of children with convulsive status epilepticus: a Meta analysis.
- Author:
Rui SHI
1
;
Huai-Qing YIN
;
Zhuan-Zhuan WANG
1
Author Information
1. First Clinical Medical College, Shanxi Medical University, Taiyuan 030000, China.
- Publication Type:Meta-Analysis
- MeSH:
Anticonvulsants/adverse effects*;
Child;
Humans;
Levetiracetam/therapeutic use*;
Pharmaceutical Preparations;
Phenytoin/adverse effects*;
Status Epilepticus/drug therapy*
- From:
Chinese Journal of Contemporary Pediatrics
2021;23(4):356-362
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically evaluate the efficacy and safety of levetiracetam (LEV) versus phenytoin (PHT) as second-line drugs for the treatment of convulsive status epilepticus (CSE) in children.
METHODS:English and Chinese electronic databases were searched for the randomized controlled trials comparing the efficacy and safety of LEV and PHT as second-line drugs for the treatment of childhood CSE. RevMan 5.3 software was used for data analysis.
RESULTS:Seven studies with 1 434 children were included. The Meta analysis showed that compared with the PHT group, the LEV group achieved a significantly higher control rate of CSE (
CONCLUSIONS:LEV has a better clinical effect than PHT in the treatment of children with CSE and does not increase the incidence rate of adverse events.
